Connect Biopharma Holdings
CNTB
17 hedge funds and large institutions have $2.4M invested in Connect Biopharma Holdings in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
54% more capital invested
Capital invested by funds: $1.56M → $2.4M (+$844K)
31% more funds holding
Funds holding: 13 → 17 (+4)
0.72% less ownership
Funds ownership: 5.12% → 4.4% (-0.72%)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
AlphaCore Capital
La Jolla,
California
|
+$63.8K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$49.4K |
| 3 |
KWM
Koa Wealth Management
Encinitas,
California
|
+$39.5K |
| 4 |
Renaissance Technologies
New York
|
+$23K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$217K |
| 2 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$148K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.93K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.7K |
CNTB Hedge Fund Activity: Q2 2025 in Review
17 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q2 2025, worth a combined $2.4M — up 54% from $1.56M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CNTB positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was AlphaCore Capital, opening a new position worth an estimated $63.8K. The largest seller was BML Capital Management, cutting an estimated $217K.
- 17 institutional investors held Connect Biopharma Holdings (CNTB) as of Q2 2025, up from 13 in Q1 2025.
- Funds reported $2.4M of Connect Biopharma Holdings stock for Q2 2025, up 54% quarter-over-quarter.
- 6 funds opened new Connect Biopharma Holdings positions in Q2 2025 and 1 closed out, a net change of +5 holders.
- The largest Connect Biopharma Holdings buyer in Q2 2025 was AlphaCore Capital, an estimated $63.8K added.
- The largest Connect Biopharma Holdings seller in Q2 2025 was BML Capital Management, an estimated $217K sold.
Based on aggregated 13F filings for Q2 2025.